Six-week antibiotic tx effective for diabetic foot osteomyelitis

Six-week antibiotic tx effective for diabetic foot osteomyelitis

(HealthDay)—For patients with diabetic foot osteomyelitis (DFO), six weeks of antibiotic therapy seems as effective as 12 weeks of treatment, according to a study published online Nov. 20 in Diabetes Care.

Alina Tone, M.D., from Gustave Dron Hospital in Tourcoing, France, and colleagues compared the effectiveness of six versus 12 weeks of in 40 with nonsurgically-treated DFO enrolled in a . During the monitoring period, remission of osteomyelitis was defined as complete and persistent healing of the wound, absence of recurrent infection at the initial site or that of adjacent rays, and no need for surgical bone resection or amputation at the end of at least 12 months of follow-up.

The researchers found that remission was obtained in 65 percent of patients with no significant differences between patients treated for six versus 12 weeks (12/20 treated for six weeks versus 14/20 treated for 12 weeks; P = 0.50). No significant parameters were found in association with patient outcome. There were fewer patients who experienced gastrointestinal adverse events related to antimicrobial therapy among those treated for six weeks versus those treated for 12 weeks (15 versus 45 percent; P = 0.04).

"The present multicenter prospective randomized study provides data suggesting that six-week duration of antibiotic therapy may be sufficient in patients with DFO for whom nonsurgical treatment is considered," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2014 HealthDay. All rights reserved.

Citation: Six-week antibiotic tx effective for diabetic foot osteomyelitis (2014, December 10) retrieved 4 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Simeprevir-based therapy offers cost-effective alternative in treatment of hepatitis C


Feedback to editors